Cargando…

Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells

Multiple myeloma (MM) is an incurable malignancy often associated with primary and acquired resistance to therapeutic agents, such as proteasome inhibitors. However, the mechanisms underlying the proteasome inhibitor resistance are poorly understood. Here, we elucidate the mechanism of primary resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsubaki, Masanobu, Takeda, Tomoya, Matsuda, Takuya, Seki, Shiori, Tomonari, Yoshika, Koizumi, Shoutaro, Nagatakiya, Miki, Katsuyama, Mai, Yamamoto, Yuuta, Tsurushima, Katsumasa, Ishizaka, Toshihiko, Nishida, Shozo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823718/ https://www.ncbi.nlm.nih.gov/pubmed/33406639 http://dx.doi.org/10.3390/biomedicines9010033

Ejemplares similares

Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice
por: Kato, Natsuki, et al.
Publicado: (2020)

Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells
por: Tabata, Mitsuki, et al.
Publicado: (2020)

Dimethyl Fumarate Induces Apoptosis via Inhibition of NF-κB and Enhances the Effect of Paclitaxel and Adriamycin in Human TNBC Cells
por: Tsurushima, Katsumasa, et al.
Publicado: (2022)

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2019)

The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2020)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple-negative breast cancer metastasis via the inhibition of CXCR4 expression
por: Takeda, Tomoya, et al.
Publicado: (2023)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2021)

Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study
por: Shen, Man, et al.
Publicado: (2021)

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma
por: Yanae, Masashi, et al.
Publicado: (2011)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
por: Sampat, Parth J., et al.
Publicado: (2021)

Ixazomib-induced Sweet’s syndrome: A case report
por: Bellemare, Jeanne, et al.
Publicado: (2023)

Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation
por: Tsubaki, Masanobu, et al.
Publicado: (2014)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
por: Girnius, Saulius K., et al.
Publicado: (2023)

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2018)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
por: Rifkin, R. M., et al.
Publicado: (2022)

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
por: Varga, Gergely, et al.
Publicado: (2019)

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Zhe, et al.
Publicado: (2023)

Bortezomib is an effective enhancer for chemical probe-dependent superoxide detection
por: Matsumoto, Misaki, et al.
Publicado: (2022)

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines
por: Tsubaki, Masanobu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_484q5741j1uinguti5ulh12hil